Shedding new light on the science of motion
BKIN Technologies is transforming the assessment of brain injuries by putting cutting-edge robotics technology into the hands of neuroscientists and clinician-scientists around the world. Our KINARM Labs give our customers a “window” on brain function that is objective and quantitative – allowing them to study, with exquisite precision, the sensory, motor and cognitive impact of a wide range of brain injuries and diseases, such as: stroke, cardiac arrest, transient ischemic attack, traumatic brain injury, and Parkinson’s disease.
Our team is comprised of experts in neuroscience, engineering, physiology, electronics, machining and software development. We work closely with basic and clinical researchers to integrate our technologies into their unique research programs to achieve their goals.
BKIN Technologies developed out of a shared aspiration to shed light on the field of sensorimotor neuroscience.
Unsatisfied with the available tools for conducting research on sensorimotor performance and neurologically based motor deficiencies, the BKIN team set out to revolutionize the way the scientific community assesses sensorimotor dysfunction. By combining extensive knowledge and experience with the resources provided by Queen’s University, the company had its initial aspirations in the form of advanced sensorimotor assessment technologies.
Ten years later, our curiosity and dedication to this field of study has set a new standard for the breadth and depth of tools supporting sensorimotor research. BKIN is thriving and delivering not just robotic arms, but advanced technology labs complete with fully automated operating control software Dexterit-E, and integrated gaze-tracking and force plates. KINARM Labs now enable behaviorography for not just for the neuroscience community, but for the clinical research community as well. Society has put a huge emphasis on the management of brain injuries, and BKIN believes there is an enormous translation opportunity available to disseminate the wealth of recent knowledge in the neuroscience field into enhanced assessment tools for clinical staff.
There is no gold-standard for functional assessment of the brain and this has resulted in a highly fractionated collection of measures based largely on visual-inspection of the patient’s behaviour or questionnaires. The result of such coarse scores is that it is next to impossible to discriminate small changes in performance. Without quantitative and objective assessment, not only is it impossible to perform an accurate diagnosis, or develop treatment plans for the injury, but also it is impossible to assess the benefit of new rehabilitative therapies if improvements in function cannot be measured.
BKIN believes, there is an immediate need to develop objective systems to quantify sensory-motor-cognitive deficits which will lead to improved treatments for brain injury and enhanced patient outcomes. With over two-dozen clinical publications now available, KINARM Labs have the potential to dramatically alter the management of brain injuries by the objective and quantitative assessment of sensory, motor and cognitive deficits using KINARM Standard Tests. KINARM Labs are in use in over two dozen research studies in over a dozen indications, such as: stroke, transient ischemic attack, traumatic brain injury, sport concussion, cardiac arrest, Parkinson’s disease and cerebral palsy.
While the company strives to translate KINARM Labs from the basic research field to the clinic, BKIN will remain loyal to its neuroscience roots. Recognizing that the basic research field of today will bring forth the clinical innovations of tomorrow, BKIN will continue to provide robust platforms for sensorimotor experimentation to ensure scientists can address the toughest questions in neuroscience today.
Questions about BKIN Products?
Please feel free to contact us, we’d be happy to help.